Dr. Patrick M. Dillon, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Dakota School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 231
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of North Dakota School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
VA license 0101247810 -
Hematology & Oncology Physician
VA license 0101247810
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
- Uva Health Prince William Medical Center Manassas, VA
- Uva Health Culpeper Medical Center Culpeper, VA
Medical groups
- Legacy Healthcare Services Inc (3,223 clinicians)
- University of Virginia Physicians Group (1,717 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 231
- Services billed
- 637
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 247 | 136 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 81 | 27 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 31 |
| Established patient office or other outpatient visit, 20-29 minutes | 56 | 51 |
| New patient office or other outpatient visit, 60-74 minutes | 40 | 40 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 18 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Charlottesville, VA | 139 |
| Tamoxifen Citrate Other prescribers in Charlottesville, VA | 43 |
| Kisqali (ribociclib succinate) | 30 |
| Ondansetron Hcl Other prescribers in Charlottesville, VA | 26 |
| Verzenio (abemaciclib) | 22 |
| Dexamethasone Other prescribers in Charlottesville, VA | 22 |
| Prochlorperazine Maleate Other prescribers in Charlottesville, VA | 20 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Charlottesville, VA | 15 |
| Anastrozole Other prescribers in Charlottesville, VA | 15 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Charlottesville, VA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $78.80 in total to this clinician.
| Lilly USA, LLC | $78.80 |
|---|
| Food and Beverage | $78.80 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $210,366 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
AstraZeneca Pharmaceuticals LP - A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
AstraZeneca Pharmaceuticals LP - A phase 3 randomized openlabel multicenter trial of ARV471 PF07850327 vs fulvestrant in participants with estrogen receptorpositive HER2NEGATIVE advanced breast cancer whose disease progressed after prior endocrine ba…
Pfizer Inc. - EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)
Stemline Therapeutics Inc. - A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04622319 - Phase 12A dose escalation finding and expansion study evaluating safety tolerability pharmacokinetics pharmacodynamics and anti tumor activity of PF07104091 as a single agent and in combination therapy
Pfizer Inc. - A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast C…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.